ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--NeoChord, Inc., a leader in advancing the treatment of minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass, today announced that David H. Adams, MD, and Michael A. Borger, MD, PhD, will serve as national co-principal investigators of the company’s US pivotal trial scheduled to commence later this year. “NeoChord is very fortunate to have the leadership of two world-renowned surgeon-scientists directing the clinical investigation of the NeoChord DS1000 system,” said David Chung, President and CEO of NeoChord.
